Capability
Equipped with multiple technology platforms and regulatory compliance, Adimmune leverages the strengths at the international level
9
International
certificates
The Tanzi manufacturing plants receive PIC/S GMP certificates from competent authorities around the world. Our official membership in the international organizations enables us to play a game-changing role in vaccine development
8
Strategic
partners
Adimmune is in close collaboration with research institutes in Taiwan and around the world
5
Technology
platforms
Successful quality system
Quality Control
The Quality Control team supports the production of high-quality biopharmaceutical products through optimized processes and instruments.
Safety First
Sterility testing is crucial for the safe human use of pharmaceutical products. Our sterility test is performed in a qualified isolator, providing the highest test condition.
The Pillars of Pharmaceutical Production
Our environmental and utility monitoring (HVAC systems, water systems, steam, gas, etc.) are maintained under strict PIC/S GMP requirements. In addition to the routine monitoring of facility-related samples, we maintain a database of environmental isolates from our facility. These data provide essential information for our routine assessment of the validity of the cleaning process.
Quality Lies In The Details
Analytical testing is performed on samples across the entire manufacturing process, including raw material release, in-process control, batch/product release, and product stability. All the analytical test methods are compliant with ICH guidelines.
Publication Library
Hsieh HC, Chen CC, Liu WC, Wu SC*. Intranasal booster with SARS-CoV-2 RBD Protein fused to E. coli enterotoxin A subunit after primary mRNA vaccination in mice. Vaccine 2024;42:126448.
Hong HC, Tan WF, Lin WS, Wu SC*. Glycan masking of NTD loops with a chimeric RBD of the spike protein as a vaccine design strategy against emerging SARS-CoV-2 Omicron variants. J Med Virol. 2024 Sep;96(9):e29893.
Hsieh HC, Chen CC, Chou PH, Liu WC, Wu SC*. Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit. Antiviral Res. 2023 Dec;220:105752.
Huang SH, Chen YT, Lin XY, Ly YY, Lien ST, Chen PH, Wang CT, Wu SC, Chen CC, Lin CY. In silico prediction of immune-escaping hot spots for future COVID-19 vaccine design. Sci Rep. 2023 Aug 18;13(1):13468.